GlassScriptPhysician profile
Igor Matthew Cherches
NPI 1942295522
$110,981.04
in general payments reported to CMS, 2019-2025
77 companies · $6,457 in 2025
The $6,457 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $7,492 · 2021: $10K · 2022: $14K · 2023: $13K · 2024: $6,697 · 2025: $6,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,935 · Consulting Fee: $900 · Travel and Lodging: $625 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,364.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,935.00 |
| Consulting Fee | $900.00 |
| Travel and Lodging | $625.40 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $77,356.51 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,047.96 | 2019-2025 | |
| Ucb, INC. | $2,035.33 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Alexion Pharmaceuticals, INC. | $1,862.76 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $1,643.54 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $1,603.27 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Amgen INC. | $1,601.59 | 2019-2025 | Uplizna |
| Abbvie INC. | $1,570.32 | 2021-2025 | Qulipta, Botox |
| Emd Serono, INC. | $1,495.12 | 2019-2025 | Mavenclad |
| Amneal Pharmaceuticals LLC | $1,449.21 | 2019-2024 | Rytary |
| Grifols USA, LLC | $1,267.69 | 2019-2025 | Gamunex-C |
| Sunovion Pharmaceuticals INC. | $1,259.80 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,051.82 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Pfizer INC. | $1,048.63 | 2019-2025 | |
| Csl Behring | $998.42 | 2019-2025 | Hizentra |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Cherches listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.